Is KYMR or MOLN more undervalued in 2026?

CirclFi compares Kymera Therapeutics, Inc. (KYMR) and Molecular Partners AG (MOLN) using 13 institutional-grade valuation models. KYMR has a Quality of Company score of 7.2/10 while MOLN scores 4.7/10.

Which is a better buy — KYMR or MOLN?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do KYMR and MOLN valuations compare?

KYMR at $81.46 and MOLN at $4.00 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

KYMR vs MOLN Valuation Comparison 2026 — Intrinsic Value Analysis

KYMR

Biological Products, (No Diagnostic Substances)

Kymera Therapeutics, Inc.

Quality

7.2

out of 10

Value Trap

LOW

Price

$81.46

Last close

Models

12/13

Active

MOLN

Biological Products, (No Diagnostic Substances)

Molecular Partners AG

Quality

4.7

out of 10

Value Trap

LOW

Price

$4.00

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	KYMR Fair Value	KYMR Upside	MOLN Fair Value	MOLN Upside
Bayesian DCF	Intrinsic	$18.29	-77.6%	$1.13	-71.8%
Earnings Power Value	Intrinsic	$38.43	-54.7%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$12.67	-84.4%	$1.69	-57.9%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for KYMR vs MOLN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KYMR vs MOLN — Which Stock Is More Undervalued?

KYMR scores higher with a 7.2/10 quality rating vs MOLN's 4.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Kymera Therapeutics, Inc. (KYMR) and Molecular Partners AG (MOLN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KYMR currently trades at $81.46 with a QOC of 7.2/10, while MOLN trades at $4.00 with a QOC of 4.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).